Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T61729 |
Terazosin
|
||
Terazosin, a quinazoline derivative, is an orally active and competitive antagonist of α1-adrenoceptors. Its mechanism of action involves relaxing blood vessels and promoting bladder opening. Terazosin exhibits therapeutic potential for treating benign prostatic hyperplasia (BPH) and high blood pressure [1][2][3]. | |||
T0197 |
Terazosin hydrochloride
盐酸特拉唑嗪,Terazosin HCl,Terazosine,Blavin,Hytrin,Zayasel,Fosfomic |
Adrenergic Receptor | GPCR/G Protein; Neuroscience |
Terazosin hydrochloride (Hytrin) 是一种竞争性和口服活性的 α1-肾上腺素受体拮抗剂,是一种喹唑啉衍生物。它通过舒张血管和打开膀胱来起作用。它可用于良性前列腺增生和高血压的研究。 | |||
T6701 |
Terazosin hydrochloride dihydrate
Flotrin dihydrate,Terazosin HCl Dihydrate,Dysalfa dihydrate,Heitrin dihydrate,盐酸特拉唑嗪(二水合物) |
Adrenergic Receptor | GPCR/G Protein; Neuroscience |
Terazosin hydrochloride dihydrate (Heitrin dihydrate) 是一种竞争性和口服活性的 α1-肾上腺素受体(α1-adrenoceptor) 拮抗剂,是一种喹唑啉衍生物,通过舒张血管和打开膀胱的方式起作用。它可用于研究良性前列腺增生 (BPH) 和高血压。 | |||
T12643 |
(R)-Terazosin
(R)-特拉唑嗪,盐酸特拉唑嗪 |
Adrenergic Receptor | GPCR/G Protein; Neuroscience |
(R)-Terazosin 是一种 Terazosin 的活性 R 型对映体, 是 α1-肾上腺素受体拮抗剂,对 α1a,α1b 和α1d-肾上腺素受体的Ki 分别为 6.51 nM,1.01 nM 和 1.97 nM。 | |||
T12815 |
(S)-Terazosin
|
Adrenergic Receptor | GPCR/G Protein; Neuroscience |
(S)-Terazosin is an active S-enantiomer of Terazosin. (S)-Terazosin is a potent and high-affinity antagonist of α-adrenoceptor(α1a, α1b and α1d-adrenoceptor with Ki values of 3.91 nM, 0.79 nM and 1.16 nM, respectively). | |||
T37817 |
Terazosin dimer impurity dihydrochloride
|
||
Terazosin dimer impurity dihydrochloride, a dimeric form of Terazosin, is a chemical impurity found in Terazosin. Terazosin itself is a derivative of quinazoline and acts as a competitive and orally active α1-adrenoceptor antagonist[1]. | |||
T15688 |
L-771688
SNAP 6383 |
Adrenergic Receptor | GPCR/G Protein; Neuroscience |
L-771688(SNAP 6383) 是一种新型有效和选择性的 α1A-肾上腺素受体拮抗剂, Ki 值为 0.43±0.02 nM。L-771688 KE 用于治疗良性前列腺增生。 |